Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5708-5716

  Lin, Jules ^a   Lin, Lin ^a   Thomas, Dafydd G ^a   Greenson, Joel K ^a   Giordano, Thomas J ^a   Robinson, Gregory S ^c   Barve, Ruteja A ^c   Weishaar, Frank A ^c   Taylor, Jeremy M G ^b   Orringer, Mark B ^a   Beer, David G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELAMONA ANTIGEN A2B; MELANOMA ANTIGEN; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN A1; MELANOMA ANTIGEN A10; MELANOMA ANTIGEN A12; MELANOMA ANTIGEN A3; MELANOMA ANTIGEN A4; MELANOMA ANTIGEN A6; MELANOMA ANTIGEN A9; MESSENGER RNA; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BARRETT ESOPHAGUS; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; DNA SEQUENCE; ESOPHAGUS CARCINOMA; GASTROINTESTINAL CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL;

ADENOCARCINOMA; ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, NEOPLASM; BARRETT ESOPHAGUS; BLOTTING, WESTERN; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; METAPLASIA; MICE; MICE, NUDE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 4444319526     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0468     Document Type: Article

References (27)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (Phila) 1998;83:2049-53.
2. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash DC) 1991;254:1643-7.
3. Chomez P, De Backer O, Bertrand M, et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
4. Chomez P, Williams R, De Backer O, Boon T, Vennstrom B. The SMAGE gene family is expressed in post-meiotic spermatids during mouse germ cell differentiation. Immunogenetics 1996;43:97-100.
5. Ohman Forslund K, Nordqvist K. The melanoma antigen genes: any clues to their functions in normal tissues? Exp Cell Res 2001;265:185-94.
6. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
7. Dutoit V, Rubio-Godoy V, Dietrich PY, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001;61:5850-6.
8. Tatsumi T, Kierstead LS, Ranieri E, et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003;9:947-54.
9. Rimoldi D, Salvi S, Reed D, et al. cDNA and protein characterization of human MAGE-10. Int J Cancer 1999;82:901-7.
10. Romero P. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Springer Semin Immunopathol 1996;18:185-98.
11. Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol 1999;29:602-7.
12. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
13. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
14. Rockett JC, Larkin K, Damton SJ, Morris AG, Matthews HR. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 1997;75:258-63.
15. Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 1997;57:5571-8.
16. Stoner GD, Kaighn ME, Reddel RR, et al. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res 1991;51:365-71.
17. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
18. Risinger JI, Maxwell GL, Chandramouli GV, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63:6-11.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
21. Kocher T, Schultz-Thater E, Gudat F, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-9.
22. Sahin U, Tureci O, Chen YT, et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998;78:387-9.
23. Crowley NJ, Vervaert CE, Seigler HF. Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T cells. Cancer Res 1992;52:394-9.
24. Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD Jr. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Surgery 1990;108:919-29.
25. Walker W, Gallagher G. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice. Clin Exp Immunol 1995;101:494-501.
26. Chen HS, Qin LL, Cong X, et al. Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003;11:145-8.
27. Rousseau P, Le Discorde M, Mouillot G, et al. The 14 bp deletion-insertion polymorphism in the 3′ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003;64:1005-10.